Aurenar’s V-Link received FDA breakthrough device designation after early clinical data suggested it reduced cerebral vasospasm by more than 40%, according to the report. The device is designed as a non-invasive nerve stimulation therapy intended to prevent brain bleed complications. The company is moving the technology toward broader adoption in neurocritical care settings where vasospasm is a key complication after certain brain hemorrhage events. The breakthrough designation signals the FDA’s interest in the device’s potential for earlier review pathways as clinical evidence matures.